Bioequivalence of antiepileptic drugs: How close is close enough?

Current Neurology and Neuroscience Reports

Volumn 9, Issue 4, 2009, Pages 333-337

  Gidal, Barry E ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; GENERIC DRUG; LAMOTRIGINE; PHENYTOIN;

AREA UNDER THE CURVE; BIOEQUIVALENCE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG INDUSTRY; DRUG PURITY; DRUG QUALITY; DRUG SOLUBILITY; GASTROINTESTINAL TRACT; GOOD MANUFACTURING PRACTICE; HUMAN; MAXIMUM PLASMA CONCENTRATION; PRESCRIPTION; REVIEW; STOMACH ACID SECRETION; STOMACH EMPTYING; STOMACH PH; DRUG CONTROL; ECONOMICS; EPILEPSY; HEALTH CARE COST; PHARMACOKINETICS; TREATMENT OUTCOME;

ANTICONVULSANTS; DRUG AND NARCOTIC CONTROL; DRUGS, GENERIC; EPILEPSY; HEALTH CARE COSTS; HUMANS; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 67651236885     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-009-0050-5     Document Type: Review

References (31)

1. Berg MJ: What's the problem with generic antiepileptic drugs? A call to action. Neurology 2007, 68:1245-1246.
2. Liow K, Barkley G, Pollard J, et al.: Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. Neurology 2007, 68:1249-1250.
3. Gidal BE, Tomson T: Debate: Substitution of generic drugs in epilepsy: Is there cause for concern? Epilepsia 2009, 49:56-62.
4. Bialer M: Generic products of antiepileptic drugs (AEDs): Is it an issue? Epilepsia 2007, 48:1825-1832.
5. Crawford P, Feely M, Guberman A, Kramer G: Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure 2006, 15:165-176.
6. Wilner A: Physicians underestimate the frequency of generic carbamazepine substitution: Results of a survey and review of the problem. Epilepsy Behav 2002, 3:522-525.
7. Guberman A, Corman C: Generic substitution for brand name antiepileptic drugs: A survey. Can J Neurol Sci 2000, 27:37-43.
8. Berg MJ: Abstract 2.105. Presented at the 60th annual meeting of the American Epilepsy Society. San Diego; December 1-5, 2006.
9. Haskins LS, Tomaszewski KJ, Crawford P: Patient and physician reactions to generic antiepileptic substitution in the treatment of epilepsy. Epilepsy Behav 2005, 7:98-105.
10. Papsdorf TB, Ablah E, Ram S, et al.: Patient perception of generic antiepileptic drugs in the Midwestern United States. Epilepsy Behav 2009, 14:150-153.
11. Berg MJ, Gross RA, Tomaszewski KJ, et al.: Generic substitution in the treatment of epilepsy. Case evidence of breakthrough seizures. Neurology 2008, 71:525-530.
12. Amidon GL, Lennernas H, Shah V, Crison J: A theoretical basis for a biopharmaceutics drug classification system; the correlation of in vitro product dissolution and in vivo bioavailability. Pharm Res 1995, 12:413-420.
13. Spina E: Carbamazepine: chemistry, biotransformation, and pharmacokinetics. In Antiepileptic Drugs, edn 5. Edited by Levy RH, Mattson RH, Meldrum BS, Perucca E. Philadelphia: Lippincott Williams & Wilkins; 2002:236-246.
14. DickensCM, Chen C: Lamotrigine: chemistry, biotransformation, and pharmacokinetics. In Antiepileptic Drugs, edn 5. Edited by Levy RH, Mattson RH, Meldrum BS, Perucca E. Philadelphia: Lippincott Williams & Wilkins; 2002:370-379.
15. Bialer M. Oxcarbazepine: Chemistry, biotransformation, and pharmacokinetics. In Antiepileptic Drugs, edn 5. Edited by Levy RH, Mattson RH, Meldrum BS, Perucca E. Philadelphia: Lippincott Williams & Wilkins; 2002:459-465.
16. Meyer MC, Straugh AB: Biopharmaceutical factors in seizure control and drug toxicity. Am J Hosp Pharm 1993, 50(12 Suppl 5):S17-S22.
17. Tyrer J, Eadie M, Sutherland J, Hooper W: Outbreak of anticonvulsant intoxication in an Australian city. Br Med J 1970, 4:271-273.
18. Meyer MC, Straugh AB, Jarvi EJ, et al.: The bioinequivalence of carbamazepine tablets with a history of clinical failures. Pharm Res 1992, 12:1612-1616.
19. Merer MC, Straugh AB, Mhatre RM, et al.: The relative bioavailability and in vivo-in vitro correlations for four marketed carbamazepine tablets. Pharm Res 1998, 11:1787-1791.
20. Mayer T, May TW, Altenmuller DM, et al.: Clinical problems with generic antiepileptic drugs. Clin Invest Drug 1999, 18:17-26.
21. Revankar SN, Desai ND, Bhatt AD, et al.: Comparison of absorption rate and bioavailability of two brands of carbamazepine. J Assoc Physicians India 1999, 47:699-702.
22. Gidal BE: Drug absorption Bn the elderly: biopharmaceutical considerations for antiepileptic drugs. Epilepsy Res 2006, 68S:S65-S69.
23. Birnbaum A, Hardie NA, Leppik IE, et al.: Variability of total phenytoin serum concentrations within elderly nursing home residents. Neurology 2003, 60:555-559.
24. Rosenbaum DH, Rowan J, Tuchman L, French JA: Comparative bioavailability of a generic phenytoin and Dilantin. Epilepsia 1994, 335:656-600.
25. Burkhardt RT, Leppik IE, Blesi K, et al.: Lower phenytoin serum levels in persons switched from brand to generic phenytoin. Neurology 2004, 63:1494-1496.
26. Wilder BJ, Leppik I, Hietpas TJ, et al.: Effect of food on absorption of Dilantin Kapseals and Mylan extended phenytoin sodium capsules. Neurology 2001, 57:582-589.
27. Zachry WM, Doan Quynhchau D, Clewell JD, Smith BJ: Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes. Epilepsia 2009, 50:493-500.
28. Andermann F, Duh M, Gosselin A, Paradis P: Compulsory generic switching of antiepileptic drugs: High switchback rates to branded compounds compared with other drug classes. Epilepsia 2007, 48:464-469.
29. LeLorier J, Duh MS, Paradis PE, et al.: Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Neurology 2008, 27:2179-2186.
30. Duh MS, Andermann F, Paradis PE, et al.: The consequences of generic substitution for antiepileptic drugs in a public payer setting: The case of lamotrigine. Dis Manag 2007, 10:216-225.
31. Lelorier J, Duh MS, Paradis P, et al.: Economic impact of generic substitution of lamotrigine: Projected costs in the US using findings in a Canadian setting. Curr Med Res Opin 2008, 24:1069-1081.